P3.01-65 First-Line Radical Local Therapy May Provide Additional Survival Gain for Patients With EGFR-Mutant Metastatic NSCLC Receiving TKIs

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.1625
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

OA07.05 Local Ablative Therapy Improves Survival in Patients With Synchronous Oligometastatic NSCLC Harboring EGFR Mutation Treated With EGFR-TKIs

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P002 Surgical Resection Improves the Survival of NSCLC Patients With Pleural Metastasis Treated With First-Line EGFR-TKIs

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

First-Line Osimertinib in Patients With Treatment-Naive Somatic or Germline EGFR T790M–Mutant Metastatic NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

MA15.09 Dynamic Monitoring and Predictive Value of Circulating Tumor Cells in EGFR Mutant Advanced NSCLC Patients Treated With First-Line EGFR-TKIs

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P1.13-26 First-Line Continual EGFR-TKI Plus LAT Demonstrated Survival Benefit in Egfr-Mutant NSCLC Patients With Oligoprogressive Disease

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P3.01-16 Low Dose Apatinib Combined With EGFR-TKI in Treating Advanced NSCLC After First-Generation EGFR-TKIs Treatment Failure

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Bisphosphonates Enhance Antitumor Effect of EGFR-TKIs in Patients With Advanced EGFR Mutant NSCLC and Bone Metastases

Scientific Reports
Multidisciplinary
2017English

MA15.11 Real World Biomarker Testing and Treatment Patterns in Patients With Advanced NSCLC Receiving EGFR-TKIs

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P3.13-10 Factors Associated With Long-Term Survival of Stage IV NSCLC Patients on First-Line EGFR-Targeting Therapy

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy